CUE
Cue Biopharma Inc

1,356
Loading...
Loading...
News
all
press releases
Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates
Cue Biopharma (CUE) delivered earnings and revenue surprises of +30.77% and +47.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·24d ago
News Placeholder
More News
News Placeholder
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
YmAbs Therapeutics (YMAB) delivered earnings and revenue surprises of +74.07% and +5.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·29d ago
News Placeholder
scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates
scPharmaceuticals (SCPH) delivered earnings and revenue surprises of -13.33% and -2.19%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·29d ago
News Placeholder
Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates
Zacks·4mo ago
News Placeholder
Forecasting The Future: 4 Analyst Projections For Cue Biopharma
Latest Ratings for CUE DateFirmActionFromTo Nov 2020BerenbergInitiates Coverage OnBuy May 2020StifelMaintainsBuy May 2020OppenheimerMaintainsOutperform View More Analyst Ratings for CUE...
Benzinga·1y ago
News Placeholder
Cue Biopharma to Host Business Update Call and Webcast
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate...
Globe Newswire·1y ago
News Placeholder
Navalign LLC Takes $66,000 Position in Cue Biopharma, Inc. (NASDAQ:CUE)
Navalign LLC bought a new stake in shares of Cue Biopharma, Inc. (NASDAQ:CUE Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities Exchange...
Ticker Report·1y ago
News Placeholder
Jefferies Financial Group Begins Coverage on Cue Biopharma (NASDAQ:CUE)
Jefferies Financial Group assumed coverage on shares of Cue Biopharma (NASDAQ:CUE Free Report) in a research report released on Wednesday, MarketBeat reports. The firm issued a buy rating and...
Zolmax·1y ago
News Placeholder
Cue Biopharma presenting data on lead clinical asset CUE-101 at symposium
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate...
Globe Newswire·2y ago

Latest CUE News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.